Selection criteria for genetic assessment of patients with familial melanoma.
Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarrà G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H.
J Am Acad Dermatol. 2009 Oct;61(4):677.e1-14. doi: 10.1016/j.jaad.2009.03.016.
- There is clearly a tendency of melanoma to run in families and the disease does tend to affect lighter skin and those with multiple nevi.
- 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A)
- This review tries to identify those who could benefit from genetic screening.
For full access to the free article in the Journal of American Academy of Dermatology (JAAD), click here
JAAD: click here to view abstracts from the current edition, articles in press, most cited articles and top 25 articles.
Contributors
Dr Christophe Hsu – dermatologist. Geneva, Switzerland